These studies demonstrated immune modulation and durable remissions and led to the recent approval by the FDA of anti-PD-1 antibodies, nivolumab and pembrolizumab, for use in HNSCC treatment [6–11]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.